Zobrazeno 1 - 10
of 107
pro vyhledávání: '"James N. Atkins"'
BRCA1 Protein Expression Predicts Survival in Glioblastoma Patients from an NRG Oncology RTOG Cohort
Autor:
Aidnag Z. Diaz, James N Atkins, Lydia Komarnicky, Jonathan P.S. Knisely, Steven P. Howard, David L. Rimm, Maria Vassilakopoulou, Jason A. Hanna, Veronique Neumeister, Edward Melian, Christopher J. Schultz, Corey J. Langer, Peixin Zhang, Michael D. Prados, Minhee Won, Adam P. Dicker, Luis Souhami, Walter J. Curran
Publikováno v:
Oncology
Purpose: Glioblastoma, the most common malignant brain tumor, was associated with a median survival of Methods and Materials: A TMA composed of archived glioblastoma tumors from patients treated with surgery, radiation, and non-TMZ chemotherapy, wa
Autor:
Kimmie Ng, Charles D. Blanke, Robert J. Mayer, Eileen M. O'Reilly, Brendan J. Guercio, Kaori Sato, Jeffrey A. Meyerhardt, Bert H. O'Neil, Alan P. Venook, Fang-Shu Ou, Howard S. Hochster, Sui Zhang, James N. Atkins, Blase N. Polite, Richard M. Goldberg, Erin L. Van Blarigan, Charles S. Fuchs, Donna Niedzwiecki, James Edward Shaw, Federico Innocenti, Heinz-Josef Lenz
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 37, iss 29
PURPOSE Regular physical activity is associated with reduced risk of recurrence and mortality in patients with nonmetastatic colorectal cancer. Its influence on patients with advanced/metastatic colorectal cancer (mCRC) has been largely unexplored. P
Autor:
Anthony J. Olszanski, Patrick M. Forde, Olivier Rixe, Yanyan Lou, Asha Nayak-Kapoor, David S. Hong, Vi K. Chiu, Floyd Fox, Margaret A. Marshall, Agron Collaku, Tomislav Dragovich, Rom Leidner, James N. Atkins
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 28(3)
Purpose: The aim of the study was to determine safety, antitumor activity, and pharmacodynamic profile of mogamulizumab, an anti-CCR4 monoclonal antibody targeting effector regulatory T cells (Treg) in combination with the checkpoint inhibitor nivolu
Autor:
Kouros Owzar, Bryan P. Schneider, Donna Niedzwiecki, Yukihide Momozawa, Megan Li, Heinz-Josef Lenz, Chen Jiang, Michiaki Kubo, Flora Mulkey, Deanna L. Kroetz, Paula N. Friedman, Howard L. McLeod, Fei Shen, Alan P. Venook, William Kevin Kelly, Susan Halabi, Bert H. O'Neil, Howard S. Hochster, Federico Innocenti, Mark J. Ratain, Hope S. Rugo, James N. Atkins
Publikováno v:
Clinical Cancer Research. 24:4734-4744
Purpose: Bevacizumab is a VEGF-specific angiogenesis inhibitor indicated as an adjunct to chemotherapy for the treatment of multiple cancers. Hypertension is commonly observed during bevacizumab treatment, and high-grade toxicity can limit therapy or
Autor:
Benson Al Bowen, Bert H. O'Neil, Alan P. Venook, Blase N. Polite, Robert J. Mayer, Sui Zhang, Michael Pollak, Eileen M. O'Reilly, James Edward Shaw, Charles D. Blanke, Donna Niedzwiecki, Brian C. Mullen, Fang-Shu Ou, James N. Atkins, Jeffrey A. Meyerhardt, Charles S. Fuchs, Heinz-Josef Lenz, Justin C. Brown, Andrew B. Nixon, Richard M. Goldberg, Federico Innocenti, Brendan J. Guercio
Publikováno v:
JNCI Cancer Spectrum
Background Energy balance-related biomarkers are associated with risk and prognosis of various malignancies. Their relationship to survival in metastatic colorectal cancer (mCRC) requires further study. Methods Baseline plasma insulin-like growth fac
Autor:
Sui Zhang, Charles D. Blanke, Justin C. Brown, Robert J. Mayer, James N. Atkins, Donna Niedzwiecki, James Edward Shaw, Federico Innocenti, Brian C. Mullen, Heinz-Josef Lenz, Jeffrey A. Meyerhardt, Fang-Shu Ou, Charles S. Fuchs, Blase N. Polite, Bert H. O'Neil, Alan P. Venook, Howard S. Hochster, Richard M. Goldberg, Eileen M. O'Reilly, Brendan J. Guercio
Publikováno v:
JNCI Cancer Spectrum
BackgroundIn nonmetastatic colorectal cancer, overweight and mild-to-moderately obese patients experience improved outcomes compared with other patients. Obesity’s influence on advanced or metastatic colorectal cancer (mCRC) is relatively unexplore
Autor:
Jean Francois Boileau, Virginia F. Borges, Kathy S. Albain, Timothy David Moore, Norman Wolmark, André Robidoux, James N. Atkins, Eleftherios P. Mamounas, Reena S. Cecchini, Sandra M. Swain, Patrick J. Flynn, Joseph P. Costantino, Louise Provencher, Charles E. Geyer, Christopher Stokoe, Louis Fehrenbacher, Priya Rastogi, Soonmyung Paik, John Crown, Jonathan Polikoff
Publikováno v:
J Clin Oncol
PURPOSE Adjuvant trastuzumab reduces invasive breast cancer (IBC) recurrence and risk for death in patients with HER2-amplified or overexpressing IBC. A subset of patients in the landmark trastuzumab adjuvant trials who originally tested HER2-positiv
Autor:
Heinz-Josef Lenz, Blase N. Polite, Donna Niedzwiecki, Crystal S. Denlinger, Justin C. Brown, Robert J. Mayer, Sui Zhang, Jeffrey A. Meyerhardt, Fang-Shu Ou, Bert H. O'Neil, Alan P. Venook, Kimmie Ng, Federico Innocenti, Eileen M. O'Reilly, Richard M. Goldberg, Charles D. Blanke, James N. Atkins, James E. Shaw, Charles S. Fuchs
Publikováno v:
JNCI Cancer Spectrum
Background Diabetes is a prognostic factor for some malignancies, but its association with outcome in patients with advanced or metastatic colorectal cancer (CRC) is less clear. Methods This cohort study was nested within a randomized trial of first-
Autor:
Peter J. O'Dwyer, A. Bapsi Chakravarthy, Patrick J. Flynn, James D. Brierley, Daniel G. Haller, Roger Santala, Nicholas J. Petrelli, David Cella, Cynthia G. Leichman, Al B. Benson, Rashid A. Awan, Mary F. Mulcahy, Christine Cripps, Timothy E. O'Brien, Frank A. Sinicrope, Neal J. Meropol, Joel E. Tepper, James N. Atkins, Bruce J. Giantonio, Jeff A. Sloan, Robert B. Catalano, Edith P. Mitchell, Robert B. Diasio, Elin R. Sigurdson, John R. Weis, Paul J. Catalano, Lynne I. Wagner, Fengmin Zhao, Stanley R. Hamilton
Publikováno v:
Oncologist
Background The addition of bevacizumab to chemotherapy improved outcomes for patients with metastatic colon cancer. E5204 was designed to test whether the addition of bevacizumab to mFOLFOX6, following neoadjuvant chemoradiation and definitive surger
Autor:
Brendan Guercio, Sui Zhang, Alan P. Venook, Fang-Shu Ou, Donna Niedzwiecki, Heinz-Josef Lenz, Federico Innocenti, Hanna Sanoff, Michelle R. Mahoney, Bert H. O'Neil, James E. Shaw, Blase N. Polite, Howard S. Hochster, James N. Atkins, Richard M. Goldberg, Robert J. Mayer, Charles D. Blanke, Charles S. Fuchs, Jeffrey A. Meyerhardt
Publikováno v:
Cancer Research. 79:3285-3285
Background: In non-metastatic colorectal cancer, a body mass index (BMI) paradox is observed where overweight and early obese patients experience improved outcomes compared to patients with normal, low, or morbidly obese BMI. The influence of obesity